According to updated results from the phase 3 randomized RxPONDER study, postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer with one to three positive nodes and a 21-gene RS ≤ 25 (Oncotype DX) derive no further benefit from chemotherapy compared with endocrine therapy only. Conversely, premenopausal patients with the same clinical characteristics derive a ~5% absolute recurrence risk reduction from the addition of chemotherapy to endocrine therapy. However, whether the benefit is driven by chemotherapy itself or is mostly driven by chemotherapy-induced amenorrhea is debated.
Evidence suggests that chemotherapy does offer survival benefits for patients aged 70 years or older with TNBC. A recent study found that older women with TNBC who received chemotherapy had significantly improved survival compared with those who were recommended to undergo chemotherapy but did not receive it.
Learn more about adjuvant treatment for patients with early breast cancer.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani, Stefania Morganti. Fast Five Quiz: Advanced and Metastatic Breast Cancer Myths - Medscape - Apr 20, 2023.